T-Cure Bioscience is focused on advancing innovative T cell receptor (TCR) therapies aimed at treating solid tumors, particularly in the context of cancer immunotherapy. Their pipeline includes several clinical-stage programs, such as the 800TCR and 820TCR, which target specific cancer antigens associated with renal cell carcinoma and various other solid tumors. The 800TCR program leverages the HERV-E target, which is selectively expressed in 85% of clear cell renal cell carcinoma, while the 820TCR program targets the KK-LC-1 antigen, found in a range of cancers including gastric and triple-negative breast cancer. Both programs are currently undergoing clinical trials to evaluate their safety and efficacy in patients who have not responded to conventional therapies.

The company employs a sophisticated approach to TCR therapy, which involves the engineering of T cells to express high-affinity TCRs that can recognize and attack tumor cells. This process typically includes isolating a specific TCR, introducing it into a viral vector, and then transducing the patient's own T cells ex vivo. Once modified, these T cells are reinfused into the patient, where they can effectively target and eliminate cancer cells by recognizing tumor-derived peptides presented by the patient's HLA molecules. T-Cure is also exploring the development of "off-the-shelf" therapies using their identified TCRs, such as the 806TCR, which targets the NY-ESO-1 antigen, further expanding their therapeutic options in the fight against cancer.

United States

T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high likelihood of clinical efficacy.

Cancer

Digestive System Diseases

Kidney Diseases

Lung Diseases

Skin Diseases

Urogenital Diseases

T-Cure Bioscience

Renal cell carcinoma

800 TCR

Biologics

Cell Therapies

Cervical cancer

Gastric cancer

Lung cancer

Triple-negative breast cancer

820 TCR

Multiple Solid Tumors

806 TCR

821 TCR

830 TCR

California - South

California

Gene Therapy

Therapeutic

T-Cure Bioscience

Company Details